Form 4: HCA Healthcare SVP Granted Stock Appreciation Rights

HCA Healthcare's SVP & Chief Human Resources Officer, Jennifer Berres, was granted 6,206 Stock Appreciation Rights.

Summary

• Jennifer Berres, SVP & Chief Human Resources Officer of HCA Healthcare, Inc. (HCA), was granted 6,206 Stock Appreciation Rights (SARs).
• The transaction date for this grant was January 29, 2026.
• Each Stock Appreciation Right has an exercise price of $482.53.
• The SARs will vest in four equal annual installments, with the first installment beginning on January 29, 2027.
• The expiration date for these Stock Appreciation Rights is January 29, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any extraordinary operational or financial news.

Positives

• The grant of Stock Appreciation Rights aligns the executive's long-term incentives with shareholder value creation.
• The vesting schedule encourages long-term retention of a key executive.

Future Outlook

The grant of Stock Appreciation Rights with a multi-year vesting schedule indicates a long-term incentive structure for the SVP & Chief Human Resources Officer, aligning future compensation with the company's performance over the next several years.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights is a common form of equity-based compensation in the healthcare industry, used to incentivize senior executives by linking their compensation to the company's stock performance without requiring an upfront investment from the executive.

Comparison to Industry Standards

• Stock Appreciation Rights (SARs) are a standard component of executive compensation packages across various industries, including healthcare, similar to those offered by peers like Universal Health Services (UHS) or Tenet Healthcare (THC).
• The four-year vesting schedule is typical for long-term incentive plans, designed to promote executive retention and sustained performance, comparable to practices observed in large-cap companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of SARs aims to align the executive's financial interests with the company's stock performance, potentially benefiting shareholders through improved long-term value.
• Employees: No direct impact on general employees is indicated by this filing.
• Executive (Jennifer Berres): Receives a significant long-term incentive award, enhancing her overall compensation package and tying a portion of her future wealth to HCA's stock performance.

Next Steps

• The Stock Appreciation Rights will begin to vest in four equal annual installments starting January 29, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not contain information that would significantly alter the investment thesis for HCA Healthcare. It is a standard disclosure of an insider transaction, not indicative of a fundamental change in the company's prospects or valuation.

Keywords

HCA Healthcare, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, HCA